Tag Archives: Alecensa®

ASCO20 Virtual Scientific Program: Roche to present new data from clinical trials of approved and investigational medicines across 21 cancer types

Posted on 7, May 2020 by

First clinical data from tiragolumab, Roche’s novel anti-TIGIT cancer immunotherapy, in combination with Tecentriq® (atezolizumab) in patients with PD-L1-positive metastatic non-small cell lung cancer (NSCLC) Updated overall survival data for Alecensa® (alectinib), in people living with anaplastic lymphoma kinase (ALK)-positive … Read the full press release →

Posted in Healthcare, Pharma & Biotech, Science, Switzerland

Tagged , , , , , , , , , , , ,